# LivAssured

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/livassured-b-v

- Industry: Medical Devices & Equipment
- Headquarters: Leiden, Netherlands
- Website: www.nightwatchepilepsy.com
- Latest round: Series A (Sep 20, 2018)
- Investors on record: 3

## About

LivAssured B.V. is focused on enhancing the safety of individuals with epilepsy through innovative seizure detection technology, specifically the NightWatch+ device, which provides timely alerts to caregivers during sleep.Founded in 2013 in Leiden, Netherlands, LivAssured B.V. specializes in products for epilepsy management. The company has remained focused on its core mission without known pivots or subsidiary affiliations. CEO Jeroen Van Den Hout leads the team, which was founded by Asmund Tielens. The company has completed one funding round, raising an undisclosed amount in Series A funding on September 20, 2018 from notable investors, including Health Innovations, Morgan Holland Venture Partners, and Oost NL.LivAssured B.V. offers NightWatch+, a device designed to detect seizure activity during sleep. Utilizing a unique algorithm, it analyzes heart rate and movement to identify urgent seizures and notifies caregivers. The device has been validated in both residential and home settings, demonstrating a median sensitivity of 86% for adults and 100% for children. Target users include individuals with epilepsy, their caregivers, and healthcare professionals, with the device available in markets such as the Netherlands, Germany, France, and select regions in the DACH area.The company generates revenue through direct sales of NightWatch+ devices and potential subscription services for ongoing support and software updates. Its sales structure includes direct-to-consumer transactions and partnerships with healthcare institutions, ensuring accessibility for a wide range of customers, including caregivers and health facilities, with a pricing strategy aimed at recurring revenue through service agreements.LivAssured B.V. plans to further develop its product lineup, with specific upcoming enhancements to NightWatch+ aimed at improving seizure detection capabilities. The company is exploring expansion into additional European markets by 2025. The Series A funding raised in September 2018 will be strategically utilized to support these new product developments and market expansion initiatives.

## Funding rounds

- Series A, Sep 20, 2018 — Morgan Holland Venture Partners, Oost NL, Health Innovations

## Investors

- Morgan Holland Venture Partners — Series A
- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series A
- Health Innovations (https://capitalatlas.ai/funds/health-innovations) — Series A